Pharmacologic inhibition using a specific p110β inhibitor (TGX-221) inhibited growth in patient-derived renal cell carcinoma cells with endogenous PIK3CAD1067V and epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cells as well as in NIH-3T3 cells engineered to express this mutation. The gene discussed is EGFR; the disease is hereditary clear cell renal cell carcinoma.